FRNK Inhibitors
FRNK inhibitors are a class of chemical compounds that specifically target the Focal Adhesion Kinase-Related Non-Kinase (FRNK), a naturally occurring truncated variant of focal adhesion kinase (FAK). FRNK acts as a dominant-negative regulator of FAK by interfering with its signaling pathways, particularly those involved in cellular adhesion, motility, and cytoskeletal organization. FRNK lacks the catalytic kinase domain of FAK but retains its focal adhesion targeting (FAT) domain, allowing it to localize at focal adhesion sites and compete with FAK for binding partners. By inhibiting FRNK, these compounds modulate the signaling cascade related to focal adhesions, thereby influencing processes such as cell migration and adhesion dynamics.
The development and study of FRNK inhibitors involve understanding their structural specificity and how they interact with the focal adhesion components. These inhibitors typically function by altering the protein-protein interactions within the focal adhesion complex, leading to changes in cell shape, motility, and cytoskeletal integrity. The regulation of FRNK through these inhibitors plays a critical role in dissecting the molecular mechanisms behind focal adhesion turnover and cell movement, making them valuable tools in cellular biology. By targeting FRNK, these inhibitors provide insight into the broader regulatory network of cellular adhesion and the balance between FAK and FRNK in maintaining cell structure and function. The biochemical characterization of FRNK inhibitors often involves studying their effects on phosphorylation events and the modulation of downstream effectors in the signaling pathway.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine could potentially downregulate FRNK expression by causing DNA demethylation at the gene promoter region, leading to transcriptional silencing of the FRNK gene. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A may decrease FRNK gene expression by altering histone acetylation, resulting in a closed chromatin conformation that is less accessible for transcriptional machinery. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Through the activation of retinoic acid receptors, retinoic acid may downregulate the expression of FRNK by binding to retinoic acid response elements in the gene's promoter region. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
Dexamethasone could decrease FRNK expression by interacting with glucocorticoid response elements in the DNA sequence, leading to transcriptional repression of FRNK gene activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
By inhibiting PI3K, Wortmannin could lead to a downstream reduction in AKT signaling, which may be necessary for the transcriptional activity of the FRNK gene. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $150.00 $286.00 $479.00 $1299.00 $8299.00 $915.00 | 22 | |
DL-Sulforaphane may downregulate the expression of FRNK by activating transcription factors like NRF2, which may interact with antioxidant response elements in the FRNK promoter to repress its expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 could reduce the transcription of FRNK by blocking PI3K activity, leading to a decrease in the phosphorylation of AKT and subsequent downregulation of FRNK gene expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin may inhibit the mTOR pathway, leading to a reduction in cap-dependent translation, which could include a decrease in the synthesis of the FRNK protein. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 might decrease FRNK expression by specifically inhibiting MEK, which subsequently lowers ERK pathway signaling, potentially leading to reduced transcription of the FRNK gene. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 could inhibit the expression of FRNK by blocking JNK activity, which may be necessary for the activation of transcription factors that promote FRNK gene transcription. | ||||||